Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMA1-RON2L SBD1 immunogen
- Development stage
- Preclinical
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
AMA1-RON2L SBD1 immunogen (Structure-Based Design 1) is an experimental, single-component recombinant protein malaria vaccine candidate designed to elicit strain-transcending protective immunity against the blood-stage of Plasmodium falciparum. Developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), SBD1 is a structurally engineered fusion protein that mimics the naturally occurring complex between apical membrane antigen 1 (AMA1) and rhoptry neck protein 2 (RON2L), which is essential for merozoite invasion of host erythrocytes. Unlike traditional AMA1 vaccines that suffer from limited efficacy due to high genetic polymorphism, SBD1 directs neutralizing antibody responses to conserved, strain-transcending epitopes on AMA1 that are independent of the RON2L binding site. In preclinical studies, SBD1 has demonstrated improved thermostability, high production yields, and potent neutralizing activity against diverse strains of Plasmodium falciparum.
- Other names
- AMA1-RON2L SBD1AMA-1-RON2L SBD1AMA 1-RON2L SBD1SBD1 immunogenSBD-1 immunogenSBD 1 immunogenstructure-based design 1 immunogen
02
Targets
AMA1 (Apical membrane antigen 1)RON2 (Rhoptry neck protein 2)
Beyond the preview
Go deeper on AMA1-RON2L SBD1 immunogen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMA1-RON2L SBD1 immunogen.